FOR IMMEDIATE RELEASE
The National Pancreas Foundation PARTNERS WITH Ariel precision medicine to advance Pancreatic Genomic Medicine
Comprehensive genomic profiling and analysis services will support development of multiple initiatives to advance care of pancreatitis and other pancreatic diseases.
BETHESDA, MD – December 18, 2017– The National Pancreas Foundation (NPF), the only foundation comprehensively supporting patients suffering from all forms of pancreatic disease through research, patient support, community outreach and advocacy, and Ariel Precision Medicine (Ariel), an integrated genomics and digital health company focused on complex chronic diseases, today announced their intention to establish Ariel as the genetic testing partner to the NPF and explore opportunities to collaborate on a broad range of initiatives.
This partnership will assist pancreatic disease patients in obtaining genetic tests with the goal to advance understanding of these conditions, improve care, and quality of life. Ariel leverages next generation genetic sequencing technology to evaluate a number of genes associated with pancreatic disease. Genetic variants are increasingly recognized as drivers of pancreatic disease, modifiers of disease severity, and response to therapy. An aim of this partnership is to provide greater access to genomic tools in routine care of patients with pancreatic disease.
The National Pancreas Foundation and Ariel are dedicated to patients suffering from all forms of pancreatic disease – pediatric pancreatitis, acute pancreatitis, chronic pancreatitis and pancreatic cancer. Diagnosis of pancreatic disorders can be difficult and treatments are often delayed. Patients suffering from pancreatitis endure a broad spectrum of symptoms and conditions, ranging from debilitating pain to diabetes to pancreatic cancer. Therefore, there is an urgent need to advance diagnostic tools for pancreatic disease to enable early, targeted management for improved patient outcomes.
“The National Pancreas Foundation is excited for this partnership to help immediately improve patient care. Ariel is an innovative company using cutting edge techniques that has an opportunity to be a game changer.” said Matthew Alsante, Executive Director of NPF.
Jessica Gibson, CEO of Ariel said “The National Pancreas Foundation and Ariel clearly share a vision to improve the lives of patients affected by pancreatic diseases and support the clinicians and medical centers that care for them. We have the opportunity to dramatically improve the tools we are providing to clinicians and make significant progress in addressing the unique drivers of each patient’s disease, with the hope to continually advance management and target care.”
For more information about the National Pancreas Foundation and any of its programs, please visit www.pancreasfoundation.org.
About the National Pancreas Foundation
Founded in 1997, the National Pancreas Foundation provides hope for those suffering from pancreatitis and pancreatic cancer through funding cutting-edge research, advocating for new and better therapies and providing support and education for patients, caregivers and healthcare professionals. The NPF is the only foundation dedicated to patients suffering from all forms of pancreas disease. For more information visit: www.pancreasfoundation.org
Matthew Alsante, Executive Director, National Pancreas Foundation, (866) 726-2737, email@example.com
Jessica Gibson, MBA, Chief Executive Officer, ARIEL Precision Medicine, (412) 512-3225,
For a PDF version of the press release, please CLICK HERE.